Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
It discusses the emergence of new weight-loss drugs, including Novo Nordisks Wegovy and Ozempic and Eli Lillys Mounjaro, which have shown potential benefits beyond weight loss, such as reducing the risk of heart attack or stroke and possibly treating addiction
Semaglutide (Wegovy/Ozempic, Novo Nordisk) and liraglutide (Saxenda, Novo Nordisk) made up 31.4% and 35.3% of all new GLP-1 receptor agonist prescriptions in 2019, respectively
Side effects of these insulin-management drugs include weight loss of up to 30%
However, because these drugs slow gastric emptying and alter digestion, some individuals experience constipation, bloating, or nausea
Catch you at the Barre
The upside: if you can maintain the weight loss, you can often hold on to the health gains too
